From Lab to Life

For CME Information and to Claim Your Credit:  https://www.iridiumce.com/hf

Host:

• Robert Underwood, MD
  • Emergency Physician

Guest:

• Erin D. Michos, MD, MHS
  • Director of Women’s Cardiovascular Health Research
  • Associate Director of Preventive Cardiology at Johns Hopkins University
  • Co-Director of the IMPACT Center at Johns Hopkins University
  • Co-Editor-in-Chief of the American Journal of Preventive Cardiology

Supported by:

• Independent educational grant from Merck, Sharp, and Dohme

Episode Overview:
In this episode, Dr. Robert Underwood and Dr. Erin Michos explore innovative strategies and cutting-edge therapies for managing worsening heart failure, focusing on novel treatment approaches, emerging medical devices, and advancements in the use of monitoring technology.

Key Takeaways:

• Edema in Worsening Heart Failure:
  • Edema is a key sign of worsening heart failure, driven by the overstimulation of the renin-angiotensin-aldosterone system (RAS) and sympathetic nervous system, leading to sodium and water retention.
  • As heart failure progresses, natriuretic peptides become less effective, causing more fluid retention and adverse remodeling of the heart, vasculature, and kidneys.
• Role of Diuretics:
  • Diuretics are the cornerstone for managing edema in heart failure. Though not class 1 indicated for heart failure itself, they are essential for decongestion and preventing hospitalization.
  • Commonly used loop diuretics include furosemide and torsemide, but electrolyte imbalances like hypokalemia must be monitored.
• Soluble Guanylate Cyclase (sGC) in Heart Failure Treatment:
  • sGC stimulators like vericiguat help regulate vascular tone, cardiac remodeling, and contractility by enhancing the production of cyclic GMP, which promotes vasodilation and reduces fibrosis.
  • Vericiguat, a first-in-class sGC stimulator, was approved after the VICTORIA trial and is used for patients with chronic heart failure and an ejection fraction <45%.
• The VICTORIA Trial:
  • The VICTORIA trial demonstrated that vericiguat significantly reduced hospitalizations and cardiovascular events in patients with worsening heart failure, with a favorable safety profile and similar adverse events between treatment groups.
• Monitoring Devices for Heart Failure:
  • Implantable Devices: These devices monitor pulmonary artery pressure and provide early detection of worsening symptoms. Though promising, further studies are needed, and current guidelines provide a class 2B recommendation for select patients.
  • Wearable Devices: Wearables like those that measure thoracic fluid index are gaining traction as non-invasive tools to detect heart failure deterioration early. Initial studies suggest a reduction in hospitalizations, but more research is needed.
• Future of Monitoring and AI Integration:
  • As wearable technology and smart devices evolve, there is growing potential for AI to process the massive amounts of data generated, turning it into actionable insights to help manage heart failure and improve patient outcomes.

Next Episode Teaser:
In the next episode, the panel will explore more advanced heart failure treatments and discuss the future role of AI in heart failure management.

Follow Us:
Stay updated on upcoming episodes and MedEd threads by following Iridium on X (formerly Twitter), Facebook, and LinkedIn.

For CME Information and Claim Your Credit Before January 31, 2025:  https://www.iridiumce.com/hf-podone

Host:

• Bob Underwood, MD
  • Emergency Physician

Guests:

• Deepak Bhatt, MD, MPH
  • Director of Mount Sinai Heart
  • Inaugural Dr. Valentin Fuster Professor of Cardiovascular Medicine
• Erin Michos, MD, MHS
  • Director of Women's Cardiovascular Health Research
  • Associate Director of Preventive Cardiology at Johns Hopkins University
  • Co-Director of the Impact Center at Johns Hopkins University
  • Co-Editor in Chief of the American Journal of Preventive Cardiology

Supported by:

• Independent educational grant from Merck, Sharp, and Dohme

Episode Overview:
In this episode, the panel discusses the diagnosis, prognosis, and progression of worsening heart failure, along with new diagnostic techniques and treatment strategies. They highlight the disparities in heart failure outcomes and the importance of early detection and treatment.

Key Takeaways:

• Epidemiology of Heart Failure:
  • Around 6.7 million Americans have heart failure, and this number is increasing.
  • Heart failure is often referred to as an epidemic due to its prevalence and poor prognosis.
• Disease Progression:
  • Heart failure progresses through four stages (A-D). Worsening heart failure occurs when patients experience increasing symptoms despite optimal treatment.
  • Half of the cases involve preserved ejection fraction (HFpEF), and the other half involve reduced ejection fraction (HFrEF).
• Prognosis of Worsening Heart Failure:
  • Prognosis is poor, with a five-year mortality rate of 50%. Worsening heart failure can increase mortality rates threefold and hospitalizations sixfold.
• Diagnosis:
  • Worsening heart failure is often diagnosed through acute cardiovascular care needs, such as hospitalization or intravenous diuretics.
  • Biomarkers like BNP or NT-proBNP, echocardiograms, and imaging techniques aid in diagnosis.
• New Diagnostic Techniques:
  • Point-of-care ultrasound (POCUS) and imaging methods like echocardiograms can detect systemic venous congestion and pulmonary edema, providing valuable insights into heart failure progression.
• Role of Ejection Fraction:
  • Ejection fraction (EF) helps categorize heart failure and guides treatment. New categories such as mid-range EF (41-49%) are emerging.
  • Despite some limitations, EF remains an important tool for diagnosis and treatment decisions, though future advancements like AI could provide more precise categorizations.
• Looking Ahead:
  • Upcoming episodes will explore the role of monitoring devices in heart failure management, including invasive and non-invasive technologies.

Next Episode Teaser:
The discussion continues with a focus on monitoring devices and their role in heart failure management, as well as the future integration of AI in diagnostics.

Follow Us:
Stay updated on upcoming episodes and corresponding MedEd threads on X (formerly Twitter), Facebook, and LinkedIn.

For CME Information & Credit Visit: https://www.iridiumce.com/mastering-the-complexity-of-aml-tx-podcast-2

Summary:

This program discusses the complexities of Acute Myeloid Leukemia (AML) treatment, focusing on the role of transplantation, factors influencing transplant success, and the importance of shared decision-making between patients and healthcare providers. The conversation includes a case study on a patient with a FLIT3 ITD mutation, exploring treatment options and the necessity of balancing efficacy, safety, and quality of life in treatment decisions.

Takeaways:

• Transplant is the main consolidative option for younger patients.
• Factors influencing transplant success include donor and recipient characteristics.
• Shared decision-making enhances patient engagement and satisfaction.
• Patients often have concerns about treatment side effects.
• FLIT3 ITD mutation significantly impacts treatment strategy.
• Transplant remains a curative option for most AML cases.
• Managing treatment-related toxicities is crucial for patient care.
• Patient education helps alleviate treatment-related anxieties.
• Quality of life is a critical consideration in treatment planning.
• Emerging therapies are changing the landscape of AML treatment.

Sound Bites

• "Transplant has become the main consolidative option."
• "Factors that impact transplant success are numerous."
• "Shared decision-making is crucial in AML management."

For CME Information & Credit Visit: https://www.iridiumce.com/leveling-up-pbc-podcast-2

Summary:
This conversation delves into the management of Primary Biliary Cholangitis (PBC), focusing on the role of biomarkers in treatment, the impact of pruritus on patients' quality of life, and the latest strategies for managing this condition. The discussion highlights the importance of effective monitoring and treatment options, as well as the need for new therapies to address the challenges faced by patients with PBC.

Takeaways:

• Biomarkers are crucial for monitoring PBC progression.
• Alkaline phosphatase and bilirubin are key indicators.
• UDCA is the first-line treatment for PBC.
• Pruritus affects up to 75% of PBC patients.
• Antihistamines are ineffective for PBC-related pruritus.
• Colestyramine is the first-line therapy for pruritus.
• New therapies for pruritus are in development.
• Patient quality of life is significantly impacted by pruritus.
• Real-world evidence shows under-treatment of pruritus.
• Effective management strategies are essential for patient adherence.

Sound Bites:

• "Biomarkers play a key role in the management of PBC."
• "Pruritus significantly impacts the lives of patients with PBC."
• "Antihistamines are not effective for PBC-related pruritus."

Clinical Resource Tool: https://www.iridiumce.com/leveling-up-pbc-management-resource 

For CME Information & Credit Visit: https://www.iridiumce.com/mastering-the-complexity-of-aml-tx-podcast-1

Summary:

This conversation explores the complexities of Acute Myeloid Leukemia (AML) treatment, focusing on advancements in diagnosis, the importance of timely treatment, understanding remission and measurable residual disease (MRD), and the evolving strategies in treatment decision-making. Dr. Courtney DiNardo discusses the significance of genetic and cytogenetic factors in guiding therapy and emphasizes the need for personalized approaches in patient care.

Takeaways:

• AML treatment has seen significant advancements in the last decade.
• Timely diagnosis and treatment initiation are crucial for patient outcomes.
• Understanding different types of remission is essential for treatment planning.
• MRD status is a key indicator of treatment success and relapse risk.
• Genetic testing plays a vital role in determining the best treatment options.
• Transplant considerations should be made early in the treatment process.
• Patient goals and preferences should guide treatment decisions.
• Age alone should not dictate treatment intensity; comorbidities matter.
• Sequential MRD testing is more beneficial than a one-time assessment.
• Future guidelines will increasingly rely on molecular and cytogenetic biomarkers.

Sound Bites:

• "Mastering the Complexity of AML Treatment"
• "12 new approvals for different AML patient populations"
• "We want to get the information back quickly"

For CME Information & Credit Visit: https://www.iridiumce.com/leveling-up-pbc-podcast-1

Summary:

This conversation focuses on Primary Biliary Cholangitis (PBC), discussing its diagnosis, differentiation from other liver diseases, and evolving treatment paradigms. The speakers emphasize the importance of personalized care and a multidisciplinary approach to manage the systemic complications associated with PBC. They also explore a real-world case study to illustrate the application of these principles in patient management.

Takeaways:

• PBC is diagnosed through serologic tests and imaging.
• Differentiating PBC from other liver diseases is crucial.
• Current treatment involves UDCA, but many patients are unresponsive.
• New treatment paradigms focus on personalized care.
• Multidisciplinary teams are essential for managing PBC complications.
• Obetacolic acid and L-epipneuronal are new treatment options.
• Patient compliance with medication is critical for treatment success.
• Systemic complications of PBC include osteoporosis and vitamin deficiencies.
• Challenges in PBC management include physician awareness and patient education.
• Personalized care can enhance patient outcomes in PBC management.

Sound Bites:

• "PBC is fairly straightforward to diagnose."
• "The current paradigm is once you diagnose PBC."
• "The new paradigm is more of a personalized care."

Clinical Resource Tool: https://www.iridiumce.com/leveling-up-pbc-management-resource